Form 4: BrainStorm CEO Chaim Lebovits Receives 1.8M RSU Grant

BrainStorm Cell Therapeutics CEO Chaim Lebovits was granted 1.8 million restricted stock units, with half vesting immediately.

Summary

• CEO Chaim Lebovits acquired 1,800,000 shares of common stock via restricted stock units (RSUs).
• The grant follows a vesting schedule where 50% vested on the grant date of February 26, 2026.
• The remaining 50% of the award is scheduled to vest on the six-month anniversary of the grant date, contingent on continued employment.
• Following this transaction, the CEO's total beneficial ownership increased to 2,000,960 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative disclosure regarding executive compensation, which is standard for publicly traded companies.

Positives

• Alignment of executive interests with shareholders through significant equity-based compensation.
• Retention mechanism in place with a six-month cliff vesting requirement for the second half of the award.

Negatives

• Significant dilution impact on existing shareholders due to the issuance of 1.8 million new shares.

Risks

• Potential for future share price volatility if the executive chooses to sell vested shares.
• Dependence on continued executive leadership to meet the vesting conditions.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the equity compensation structure for the CEO.

Industry Context

StockSavvy.ai notes that equity-based compensation is standard practice in the biotechnology sector to incentivize leadership, though large grants in small-cap firms like BrainStorm often draw scrutiny regarding dilution.

Comparison to Industry Standards

• The use of RSU grants for executive compensation is consistent with standard practices for NASDAQ-listed biotechnology companies.
• The vesting schedule (50% immediate, 50% six-month) is relatively aggressive compared to typical multi-year vesting schedules seen in larger cap firms.

Stakeholder Impact

• Shareholders face immediate dilution from the issuance of 1.8 million shares.
• Employees and management are incentivized through the equity grant structure.

Next Steps

• Vesting of the remaining 50% of the RSU award on August 26, 2026, subject to continued employment.

Key Dates

Keywords

BrainStorm Cell Therapeutics, BCLI, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units, Biotech